UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033937
Receipt number R000038706
Scientific Title A study of evaluating the effect of oral intake of BARLEYmax on human skin condition. A randomized, double-blind, placebo-controlled trial.
Date of disclosure of the study information 2021/04/01
Last modified on 2021/06/11 18:21:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study of evaluating the effect of oral intake of BARLEYmax on human skin condition. A randomized, double-blind, placebo-controlled trial.

Acronym

The study of BARLEYmax on human skin condition.

Scientific Title

A study of evaluating the effect of oral intake of BARLEYmax on human skin condition. A randomized, double-blind, placebo-controlled trial.

Scientific Title:Acronym

The study of BARLEYmax on human skin condition.

Region

Japan


Condition

Condition

None

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the effect of BARLEYmax on human skin condition.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Questionnaires regarding to skin condition

Key secondary outcomes

Questionnaires regarding to feces and systemic health
Blood test(IgE, TARC, eosinophil)
Gut microbiota
Free description


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Placebo, 12 g/d for 8 weeks

Interventions/Control_2

BARLEYmax, 12 g/d for 8 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1)Individuals aged more than 20 years old.
(2)The subjects who agreed with the consent of MYCODE research.

Key exclusion criteria

(1)Individuals who are participating in other clinical trials.
(2)Individuals who may develop allergic symptoms due to wheat.

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Jun Oi

Organization

DeNA Life Science Inc.

Division name

R&D Gr.

Zip code


Address

Shibuya-Hikarie, 2-21-1, Shibuya, Sibuya-Ku, Tokyo, Japan

TEL

03-4366-7219

Email

IRB_dls@dena.com


Public contact

Name of contact person

1st name
Middle name
Last name Takashi Fujitomo

Organization

DeNA Life Science Inc.

Division name

R&D Gr.

Zip code


Address

Shibuya-Hikarie, 2-21-1, Shibuya, Sibuya-Ku, Tokyo, Japan

TEL

03-4366-7219

Homepage URL


Email

IRB_dls@dena.com


Sponsor or person

Institute

DeNA Life Science Inc.

Institute

Department

Personal name



Funding Source

Organization

Teijin Limited

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 08 Month 23 Day

Date of IRB

2018 Year 08 Month 23 Day

Anticipated trial start date

2018 Year 08 Month 30 Day

Last follow-up date

2018 Year 12 Month 10 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 08 Month 29 Day

Last modified on

2021 Year 06 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038706


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name